KYMRIAH (tisagenlecleucel)

**Product type:** Cellular Therapy

**Active ingredient:** TISAGENLECLEUCEL

**Strength:** 60000000 1/1

**Dosage form:** Injection, Suspension

**Route:** Intravenous

**Labeler:** Novartis Pharmaceuticals Corporation

**Marketing category:** BLA (BLA125646)

**Pharmacologic class:** CD19 Receptor Interactions [MoA], CD19-directed Chimeric Antigen Receptor [EPC], CD19-specific Chimeric Antigen Receptor [CS], Genetically-modified Autologous T Cells [EPC], Increased T Lymphocyte Activation [PE], T Lymphocytes, Cultured, Autologous, Genetically-modified [EXT]